Ascendis Pharma A/S (Nasdaq: ASND) is a global biopharmaceutical company founded in December 2007 and headquartered in Hellerup, Denmark (Tuborg Boulevard 12, 2900 Hellerup), with key U.S. operations in Palo Alto, CA and Princeton, NJ. The company employs approximately 1,088 professionals worldwide and focuses on rare endocrine diseases and oncology using its proprietary TransCon (Transient Conjugation) prodrug platform.
| Metric | FY 2025 | Growth |
|---|---|---|
| Total Revenue | €720 million | +98% YoY |
| Product Revenue | €684 million | - |
| - YORVIPATH (hypoparathyroidism) | €477 million | +1,561% YoY |
| - SKYTROFA (growth hormone deficiency) | €206 million (est.) | ~12% H1 YoY |
| Net Loss | €228 million | Narrowed from prior year |
| EBITDA | Not disclosed | - |
| Q4 Operating Profit | €10 million | First profitable quarter |
| Cash Position | €616 million | December 31, 2025 |
| Gross Margin | ~87% | - |
Ascendis has transitioned from a clinical-stage company to a commercial-stage rare disease leader with two FDA-approved products and a robust late-stage pipeline. The company's TransCon technology creates long-acting prodrugs that release unmodified active drugs under physiological conditions, enabling weekly dosing versus daily alternatives.
Strategic Milestones Achieved (2024-2026):
| Target | Metric | Timeline |
|---|---|---|
| 2026 Operating Cash Flow Guidance | €500 million | 2026 |
| 2030 Revenue Target | At least €5 billion annual product revenue | By 2030 |
| 2026 Initiatives | $120M share repurchase program, TransCon CNP U.S. launch (Q2 2026) | 2026 |
Ascendis Pharma A/S was founded in December 2007 in Copenhagen (Hellerup), Denmark by Jan Møller Mikkelsen (President and CEO), along with co-founders Jørgen Søberg and Torben Stavngaard. The company was incorporated in Denmark on September 21, 2006.
Initial funding came from a Series A round of $25.8 million in December 2007, led by Gilde Healthcare and TechnoStart. The founding vision centered on the TransCon technology platform, a proprietary approach to creating long-acting prodrugs.
| Year | Milestone |
|---|---|
| 2007 | Company founded; TransCon platform development begins |
| 2008 | Creation of TransCon hGH (once-weekly human growth hormone) |
| 2009 | Transition from preclinical to clinical-stage company |
| 2015 | IPO on Nasdaq, raising ~$108 million |
| 2018 | Formation of VISEN Pharmaceuticals for Greater China commercialization |
| 2021 | FDA approval of SKYTROFA for pediatric GHD |
| 2023 | European Commission approval of YORVIPATH |
| 2024 | FDA approval of YORVIPATH for U.S. adults |
| 2025 | Skytrofa label expansion to adult GHD (July 29) |
| 2026 | FDA approval of YUVIWEL for achondroplasia (February 27) |
Leadership Continuity: Jan Møller Mikkelsen has served as President and CEO continuously since founding, providing 18+ years of uninterrupted leadership.
Ascendis Pharma is a publicly traded company listed on Nasdaq (ticker: ASND) with predominant institutional ownership.
| Shareholder Category | Ownership % | Notes |
|---|---|---|
| Institutional Investors | 107-108% | 502 institutions holding ~75.8M shares |
| Insiders | 0.78% | Including CEO at ~3.1-3.2% personally |
| Retail | ~0.00% | Negligible retail ownership |
| Institution | Ownership % | Notes |
|---|---|---|
| RA Capital Management L.P. | 16.8-16.94% | Largest shareholder (~$1.6B value) |
| Viking Global Investors | 14.5-14.8% | Increased stake in 2024 |
| Westfield Capital Management | 8.45-9.03% | Second largest |
| Avoro Capital Advisors | 8.33% | Top 3 holder |
| T. Rowe Price Associates | 5.03% | Includes affiliates |
| Product | Indication | Revenue (FY 2025) | YoY Growth | Peak Sales Potential |
|---|---|---|---|---|
| YORVIPATH | Chronic hypoparathyroidism (adults) | €477M | +1,561% | Multi-billion dollar |
| SKYTROFA | Pediatric & Adult GHD | €206M (est.) | ~12% H1 YoY | $500M-$1B+ |
| YUVIWEL | Achondroplasia (children ≥2y) | Pre-launch | N/A | $500M-$1B+ |
Mechanism: Once-daily subcutaneous prodrug of parathyroid hormone (PTH) using TransCon technology; provides continuous PTH exposure, normalizing calcium and phosphorus levels.
Indications: Chronic hypoparathyroidism in adults (EU approved November 2023, U.S. FDA approved 2024)
Clinical Evidence:
Commercial Performance: €477M FY 2025 revenue, >5,300 U.S. patients enrolled, 70% payer approval rate, ~2,400 prescribing physicians by year-end 2025.
Competitive Positioning: Only approved daily PTH replacement therapy; no direct competing PTH products.
Mechanism: Once-weekly subcutaneous prodrug of somatropin using TransCon technology; releases unmodified growth hormone continuously.
Indications:
Clinical Evidence: Superior height velocity versus daily somatropin in pediatric trials; Phase III foresiGHt trial in 259 adults demonstrated non-inferiority to daily somatropin in trunk fat reduction.
Competitive Positioning: First and only once-weekly GH therapy approved for both pediatric and adult GHD; competes with daily therapies (Genotropin/Pfizer, Norditropin/Novo Nordisk) and emerging long-acting options (somapacitan).
Mechanism: Once-weekly subcutaneous prodrug of C-type natriuretic peptide (CNP); counteracts FGFR3's growth-inhibiting effects to stimulate bone growth.
Indication: Increasing linear growth in children aged ≥2 years with achondroplasia and open epiphyses (FDA accelerated approval February 27, 2026)
Clinical Evidence: Pivotal Phase 2 ApproaCH trial showed superior annualized growth velocity at week 52 versus placebo (p<0.0001); improvements in bone geometry and physical functioning.
Launch Timeline: Expected availability Q2 2026 (April-June); analyst forecast ~€50M 2026 U.S. sales.
Competitive Positioning: Competes directly with BioMarin's Voxzogo ($935M 2025 revenue); differentiates via once-weekly vs. daily dosing.
Why Priority: Blockbuster revenue driver (€477M FY 2025), first-in-class PTH replacement with no competition, strong market uptake (>5,300 U.S. patients, 70% payer approval).
Strategic Importance: Primary growth driver for 2026-2027; planned expansion to 10+ additional markets by end-2026; positioned as cornerstone of €5B 2030 revenue target.
Why Priority: Newest approval (February 27, 2026); enters large established market (Voxzogo $935M 2025 revenue); includes Rare Pediatric Disease Priority Review Voucher (monetizable at $100M+).
Strategic Importance: Key test of competitive launch execution; EU approval expected later 2026 adds international upside; ongoing patent litigation with BioMarin.
Why Priority: Label expansion to adult GHD (July 2025 approval) significantly expands addressable market; first and only weekly GH therapy for adults in market with >90% underdiagnosis.
Strategic Importance: First of "planned label expansions" with ongoing trials in Turner syndrome, ISS, SHOX deficiency, SGA.
Why Priority: Largest near-term growth opportunity for Skytrofa platform; Turner syndrome affects ~1 in 2,000-2,500 live female births globally.
Strategic Importance: Expands Skytrofa pediatric franchise into indication with high diagnostic rate; peak sales contribution estimated $200M-$500M incrementally.
Why Priority: Represents strategic expansion beyond endocrinology into high-value oncology; validates TransCon platform applicability to large markets.
Strategic Importance: Success would significantly expand long-term growth prospects beyond €5B 2030 target; Phase 2 IL-Believe trial ongoing.
Data Quality Note: Public sources provide limited granular detail on Business Unit heads and franchise-level P&L accountability below EVP level. The following represents verified executive oversight:
| Executive | Title | Scope | Status |
|---|---|---|---|
| Jay Donovan Wu | EVP & President, Ascendis US | U.S. commercial, medical affairs, government affairs | ✓ Confirmed |
| Sherrie Glass | Chief Business Officer | Global Marketing, Commercial Operations, Analytics, HEOR | ✓ Confirmed |
| Aimee D. Shu, M.D. | EVP, Endocrine & Rare Disease Medical Sciences, CMO | Medical Affairs, clinical development, global marketing approvals | ✓ Confirmed |
| Stina Singel, M.D., Ph.D. | EVP, Head of Clinical Development, Oncology | Oncology pipeline (TransCon IL-2, TLR7/8) | ✓ Confirmed |
Regional/Franchise-Level P&L Owners: Not publicly confirmed. Specific individuals accountable for Skytrofa franchise, Yorvipath franchise, YUVIWEL franchise, Europe regional, or Rest of World P&L are not identified by name in public sources.
| Program | Indication | Phase | Trial Name | Expected Milestone |
|---|---|---|---|---|
| TransCon hGH | Turner syndrome | Phase 2/3 | NCT05690386 | Data expected 2026-2027 |
| TransCon hGH | ISS, SHOX, SGA | Phase 2/3 | NCT07221851 | Data expected 2026-2027 |
| TransCon CNP | Achondroplasia (infants 0-<2y) | Pivotal Phase 2 | reACHin (NCT06079398) | Ongoing; label expansion |
| TransCon CNP | Achondroplasia (adolescents 12-18y) | Pivotal Phase 2b | teACH (NCT06732895) | Ongoing; label expansion |
| TransCon CNP | Achondroplasia (China) | Phase 2 | ACcomplisH | VISEN partnership |
| TransCon CNP | Achondroplasia (Japan) | Phase 3 | ApproaCH Japan | Teijin Pharma partnership |
| TransCon IL-2 β/γ | Various solid tumors | Phase 2 | IL-Believe (NCT05081609) | Interim data expected 2026 |
| TransCon TLR7/8 Agonist | Solid tumors (intratumoral) | Preclinical/Phase 1 | N/A | Early development |
Data Quality Note: Geographic revenue splits are not disclosed in quarterly or annual financial reports. Below estimates are derived from product launch timelines and commentary:
| Geography | Estimated Revenue (FY 2025) | % of Total | Data Quality |
|---|---|---|---|
| United States | €400-500M (estimated) | 55-70% (estimated) | Low - Not disclosed |
| Europe | €150-250M (estimated) | 20-35% (estimated) | Low - Not disclosed |
| Rest of World | €30-70M (estimated) | 5-10% (estimated) | Low - Not disclosed |
| Total Product Revenue | €684M | 100% | High - Official disclosed |
2026 Geographic Priorities:
| Company | Product | Dosing | Market Position |
|---|---|---|---|
| Ascendis | Skytrofa | Weekly SC | 6.5% U.S. volume (2024); First weekly for adult GHD |
| Pfizer | Genotropin | Daily SC | Leading market share |
| Novo Nordisk | Norditropin | Daily SC | Major competitor |
| Novo Nordisk | Somapacitan | Weekly SC | Emerging weekly option |
| Merck KGaA / EMD Serono | Saizen | Daily SC | Established competitor |
| OPKO Health | Somatrogon | Weekly SC | Approved 2021 (pediatric) |
| Therapy | Mechanism | Dosing | Market Position |
|---|---|---|---|
| Ascendis YORVIPATH | TransCon PTH replacement | Once-daily SC | Only approved PTH replacement |
| Conventional Therapy | High-dose calcium + active vitamin D | Multiple daily oral doses | Standard of care (inferior outcomes) |
| Company | Product | Mechanism | Dosing | 2025 Revenue |
|---|---|---|---|---|
| BioMarin | Voxzogo (vosoritide) | CNP analog | Daily SC | $900-935M (market leader) |
| Ascendis | YUVIWEL (navepegritide) | TransCon CNP prodrug | Weekly SC | Pre-launch (approved Feb 2026) |
| BridgeBio | Infigratinib | FGFR3 inhibitor | Oral (TBD) | Phase 3 (potential 2027 launch) |
| Target | Metric | Implication |
|---|---|---|
| 2026 Operating Cash Flow | ~€500 million | Path to sustained profitability |
| 2030 Revenue Target | At least €5 billion annual product revenue | 49% CAGR from €684M FY 2025 base |
| Share Repurchase | $120M program authorized | Confidence in growth trajectory |
| Metric | Value |
|---|---|
| Recent Stock Price | $239.92 (March 9, 2026) |
| Analyst Consensus Price Target | $256-303 (range $153-$342) |
| Upside | 15-25% from recent levels |
| 2026 Revenue Consensus | $1.3B (€1.1-1.5B range) |
| Consensus Rating | Strong Buy (11-20 analysts) |
| Company | Est. Market Cap | 2025 Revenue | Focus | Stage |
|---|---|---|---|---|
| Ascendis Pharma | ~$14-15B | €720M ($780M) | Rare endocrine diseases | Commercial + late pipeline |
| BioMarin Pharmaceutical | ~$16-18B | $3.2B | Rare genetic diseases | Established commercial |
| Vertex Pharmaceuticals | ~$110-120B | $10B+ | CF, gene editing | Dominant CF + emerging |
| Sarepta Therapeutics | ~$12-14B | $2-2.5B | Duchenne MD | Commercial + gene therapy |
| Ultragenyx | ~$3-5B | $500-700M | Rare metabolic, bone | Commercial + pipeline |
Bull Case:
Bear Case:
| Product | Indication | U.S. Patents | U.S. Exclusivity (Est.) | EU Exclusivity (Est.) | Key Risk |
|---|---|---|---|---|---|
| SKYTROFA | Pediatric & Adult GHD | 30+ patents listed | Not disclosed; est. 2035-2045+ | Not disclosed | Patent cliff in 2030s; biosimilar entry post-exclusivity |
| YORVIPATH | Hypoparathyroidism | 9 patents listed | Not disclosed; est. 2035-2045+ | Not disclosed | Patent cliff in 2030s; PTH biosimilars/analogs |
| YUVIWEL | Achondroplasia | Not yet listed (approved Feb 2026) | Orphan exclusivity ~2033; patents likely 2040s | EU decision pending | BioMarin patent litigation (case 2026-1026); adverse ruling risk |
Data Quality Note: Patent expiration dates are not disclosed in public filings. Estimated expirations based on standard 20-year terms; actual exclusivity depends on filing dates, Patent Term Extensions, pediatric exclusivity, and orphan drug exclusivity.
Ada Health's Patient Finder identifies undiagnosed patients through symptom assessment and navigates them to appropriate care, generating revenue as a percentage (8-12%) of first-year drug revenue per patient found. Ascendis Pharma's portfolio addresses rare endocrine diseases with diagnostic delay challenges, making it a strong candidate for Ada partnership.
| Metric | Value |
|---|---|
| Diagnostic Delay | 2-4 years |
| Underdiagnosis Rate | 30-40% (only 63-68% of confirmed cases treated) |
| Ada-Addressable Patients (U.S.) | 3,500-7,500 |
| Net Revenue Per Patient (U.S.) | $16,500-$19,250 annually |
| Incremental Revenue Potential | $58M-$144M annually |
Why Ada Can Surface This Condition: Parents query short stature, slow growth, growth concerns; combinable with metabolic symptoms (fatigue, hypoglycemia history in infants). GH stimulation testing is specialized and many pediatricians lack awareness.
Pitch Hook: "Pediatric growth hormone deficiency faces a 2-4 year diagnostic delay from parental concern to diagnosis, during which children fall further behind growth curves and miss critical treatment windows. Over 30-40% of true GHD cases remain undiagnosed, and even among diagnosed patients, >30% do not receive treatment. Ada's symptom assessment can surface growth failure patterns (persistent short stature + slow growth velocity + metabolic symptoms) and prompt referral for IGF-1 screening and endocrinology evaluation, identifying 3,500-7,500 undiagnosed U.S. pediatric GHD patients eligible for Skytrofa's once-weekly therapy ($16,500-$19,250 net annual revenue per patient). This represents $58M-$144M in incremental annual U.S. pediatric GHD revenue while accelerating time to treatment."
| Metric | Value |
|---|---|
| Diagnostic Delay | 1-3 years (genetic/idiopathic cases) |
| Underdiagnosis Rate | 10-20% (primarily genetic/autoimmune cases) |
| Ada-Addressable Patients (U.S.) | 5,000-12,000 |
| Net Revenue Per Patient (U.S.) | $142,500 annually |
| Incremental Revenue Potential | $700M-$1.7B annually |
Why Ada Can Surface This Condition: Hypocalcemia symptoms (muscle cramps, tetany, paresthesias) are distinctive and query-able; neuropsychiatric symptoms (anxiety, fatigue) less specific but combinable. Post-surgical cases identified via surgical follow-up, but genetic/autoimmune cases (25% of total) present with nonspecific symptoms delaying diagnosis.
Pitch Hook: "Hypoparathyroidism patients with genetic or autoimmune etiology face an estimated 1-3 years of diagnostic odyssey before receiving correct diagnosis, during which they experience debilitating muscle cramps, fatigue, and cognitive impairment while being misdiagnosed with fibromyalgia, chronic fatigue syndrome, or anxiety disorders. Ada's symptom assessment can surface hypocalcemia-related symptom patterns (tetany, paresthesias, muscle cramps combined with fatigue) and flag for calcium/PTH testing, identifying 5,000-12,000 undiagnosed U.S. patients eligible for Yorvipath's PTH replacement therapy ($142,500 net annual revenue per patient). With 70% payer approval already established and no competing PTH therapies, Ada Patient Finder can accelerate time to diagnosis and Yorvipath initiation, generating $700M-$1.7B in incremental annual revenue."
| Metric | Value |
|---|---|
| Diagnostic Delay | 5-10+ years |
| Underdiagnosis Rate | >90% (only 9.7% of confirmed cases treated) |
| Ada-Addressable Patients (U.S.) | 10,000-30,000 |
| Net Revenue Per Patient (U.S.) | $15,000-$25,000 annually |
| Incremental Revenue Potential | $150M-$750M annually |
Challenge: Symptoms (fatigue, weight gain, reduced exercise capacity, depression) are nonspecific and overlap with common conditions (metabolic syndrome, depression, hypothyroidism). Combinable patterns may help (post-TBI + fatigue + truncal obesity + reduced QoL).
Note: Medium fit score due to nonspecific symptom profile, but massive unmet need (>90% underdiagnosis) justifies Ada effort.
Reason: Achondroplasia is identified through physical phenotype at birth, not symptom-based assessment. Diagnostic delay <1 year; <5% undiagnosed prevalence. Ada's value proposition (surfacing undiagnosed patients via symptom patterns) does not apply.
Assessment: Focus partnership efforts on Yorvipath, Skytrofa pediatric GHD, and Skytrofa adult GHD where diagnostic delay and underdiagnosis are substantial.
| Drug | Indication | Fit Score | Diagnostic Delay | Incremental Revenue | Priority |
|---|---|---|---|---|---|
| SKYTROFA | Pediatric GHD | 8/10 | 2-4 years | $58M-$144M | HIGH |
| YORVIPATH | Hypoparathyroidism | 7/10 | 1-3 years | $700M-$1.7B | HIGH |
| SKYTROFA | Adult GHD | 6/10 | 5-10+ years | $150M-$750M | MEDIUM |
| TransCon hGH | Turner Syndrome (pipeline) | 7/10 | 3-7 years | $82M-$275M | MEDIUM |
| YUVIWEL | Achondroplasia | 2/10 | <1 year | <$110M | NOT RECOMMENDED |